The global microfluidics market size is expected to reach USD 73.85 billion by 2030, registering CAGR of 11.99% from 2025 to 2030, according to a new report by Grand View Research, Inc. The demand for microfluidics-based devices is expected to increase due to the introduction of improved technology such as digital microfluidics, which enables on-chip biochemical analysis. An increase in research activities undertaken by analytical and clinical researchers have also driven the demand for microfluidics device. For instance, in May 2022, a research team from the University of Minnesota developed an innovative microfluidic chip for disease diagnosing that uses a minimum number of components and can be operated wirelessly by a smartphone.
Miniature microfluidic-based tools are gaining significant popularity among consumers, which has encouraged companies to invest in their development. Since microfluidics is the underlying principle of lab-on-a-chip devices, it offers various benefits such as minimal sample volume, minimal reagent usage, reduced waste, and rapid processing. Fully automated microfluidics with enhanced functional capabilities, and robust modularity are creating growth opportunities for manufacturers operating in the market. This can be attributed to the fact that modular chips can interface with several instruments. In addition, companies operating in the field of drug discovery are striving to minimize overhead costs and timelines to offset the estimated decline in revenue owing to a significant number of drugs going off-patent.
The implementation of microfluidics is expanding in the field of diagnostics, especially in POC diagnostics. This is also supplemented by microfluidics-integrated biosensor technologies that are expected to enhance POC diagnostics. The combination of microfluidic components with POC devices is largely focused on achieving sensitivity, stability, accuracy, affordability, and obtaining minimally invasive POC technology. Microfluidic POC technologies are expected to enhance patient care by ensuring personalization, early disease detection, and easy monitoring.
In addition, COVID-19 has further upscaled the use of microfluidics. Point-of-care testing involves small equipment, regulates the process, and has limited testing cycles. This allows single or multiple research laboratory services to evaluate biological samples and diagnose harmful diseases simultaneously. In general, stage assessment and rapid detection of viral epidemics are vital to overcoming pandemic situations and diagnosing rapidly. Therefore, combining microfluidic devices with point-of-care testing enhances detection efficiency. At the same time, point-of-care testing of microfluidic chips enhances user accessibility, improves sensitivity and accuracy, and reduces the detection time, all of which are advantageous in detecting SARS-CoV-2.
Further, several acquisitions in the microfluidics industry are aimed at enhancing technologies for expanding the scope of microfluidics-related applications. In June 2021, Danaher Corporation announced that Precision NanoSystems (PNI), a Canada-based solution provider, was acquired by its life science business. PNI offered proprietary genetic toolkit platforms, including LNP delivery and nanoparticle manufacturing via the microfluidic-based platform, which further complemented the company’s portfolio of life science products.
On the other hand, high operational costs hinder the microfluidics market growth to a certain extent. The fabrication of microfluidics chips has certain issues such as open channel construction that require bonding of machine parts to form a final enclosed structure. The open channel is formed by the etching of glass or silicon. This step is slow, costly, and requires the use of aggressive chemicals. In addition, most of the microfluidic prototyping methods are not compatible with the batch process, and are also complicated and costly.
Request a free sample copy or view report summary: Microfluidics Market Report
Based on application, the medical segment held the largest revenue share in 2024. Microfluidics is a significant technology in biological analysis, chemical synthesis, and information technology.
Based on material, the polydimethylsiloxane (PDMS) segment held the highest revenue share of 36.60% in 2024. PDMS is a widely used polymer in microfluidics owing to the several advantages offered by the material.
Based on technology, Lab-on-a-chip segment held the highest market share of 37.49% in 2024. Lab-on-a-chip research has recently shown potential in cell biology.
North America microfluidics market dominated the global market with a revenue share of 42.3% in 2024. This dominance is primarily driven by strong research funding from both government bodies and private industries
Grand View Research has segmented the global microfluidics market report based on product, technology, material, application, and region:
Microfluidics Product Outlook (Revenue, USD Million, 2018 - 2030)
Microfluidic-based Devices
Microfluidic Components
Chips
Micro-pumps
Sensors
Others
Microfluidics Technology Outlook (Revenue, USD Million, 2018 - 2030)
Lab-on-a-chip
Organ-on-a-chip
Continuous Flow Microfluidics
Optofluidics & Microfluidics
Acoustofluidics & Microfluidics
Electrophoresis & Microfluidics
Microfluidics Material Outlook (Revenue, USD Million, 2018 - 2030)
Silicon
Glass
Polymer
PDMS
Others
Microfluidics Application Outlook (Revenue, USD Million, 2018 - 2030)
Medical
Pharmaceuticals
Medical Devices
In-vitro Diagnostics
Others
Non-medical
Microfluidics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Microfluidics Market
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Revitty
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Danaher
Thermo Fisher Scientific, Inc.
Abbott
Standard Biotools
thinXXS Microtechnology GmbH
"The quality of research they have done for us has been excellent..."